Aker Christopher Ray

Avg. Two Year Performance

No purchase track record

No sale track record

	1 Mo	3 Mo	6 Mo	1 Yr	2 Yr
Average Purchase Return	--	--	--	--	--
Purchase Success Rate	--	--	--	--	--
Average Sale Return	13%	28%	32%	34%	0%
Sale Success Rate	5 of 13	5 of 13	7 of 13	5 of 13	0 of 13

Regulus Therapeutics Inc.

Drugs » Drug Manufacturers - Major

Sr. VP & General Counsel:

Holdings: 10.06K shares

Sentiment

Avg. Two Year Performance

No purchase track record

No sale track record

Last Three Months:

0 Net Amount

Buy:	0	--
Sell:	0	--